RG6123 / Roche - LARVOL DELTA

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - P1; N=26; Terminated; Sponsor: Hoffmann-La Roche; Completed ➔ Terminated; Study terminated due to change in benefit-risk ratio, driven by high incidence GI toxicity in absence of clinically significant anti-tumor efficacy.

Clinical • Trial termination • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - P1; N=26; Terminated; Sponsor: Hoffmann-La Roche; N=150 ➔ 26; Trial completion date: Dec 2020 ➔ Jul 2019; Recruiting ➔ Terminated; Trial primary completion date: Dec 2020 ➔ Jul 2019

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - P1; N=26; Completed; Sponsor: Hoffmann-La Roche; Terminated ➔ Completed

Clinical • Trial completion

"$RHHBY discontinuations: RG6109 undiscl ADC; RG6123 anti-CEA MAb; RG6146 bromodomain inh; RG6148 undisclosed (Her2+ breast cancer); RG7625 cathepsin S inh" (@JacobPlieth)

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - P1; N=150; Recruiting; Sponsor: Hoffmann-La Roche; Trial completion date: Jun 2021 ➔ Dec 2020

Clinical • Trial completion date

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov) - P1; N=150; Recruiting; Sponsor: Hoffmann-La Roche; Trial completion date: Apr 2020 ➔ Jun 2021; Trial primary completion date: Oct 2019 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date